| pioglitazone / Generic mfg. |
2006-004296-35: An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment |
|
|
| Ongoing | 4 | 80 | Europe | Actos, Supralip 160, Actos, Supralip 160 | The Royal Group of Hospitals, Belfast Health and Social Care Trust, Queen\'s University Belfast | The proposed study will investigate early indicators of cardiovascular disease and diabetes in healthy, obese men without a family history of diabetes and whether these are changed by treatment with the common PPAR agonists fenofibrate andpioglitazone. | | | | |
2007-007075-16: The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - |
|
|
| Ongoing | 4 | 50 | Europe | Copegus, Actos, Pegasys, Actos, Pegasys | VU university medical center | Chronic hepatitis C infection | | | | |
| Recruiting | 4 | 1506 | RoW | Pioglitazone 45 mg | Dasman Diabetes Institute, Ministry of Health, Kuwait, Texas Diabetes Institute, Kuwait University | Covid19, Type 2 Diabetes | 06/21 | 06/21 | | |
NCT04584242: Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes |
|
|
| Recruiting | 4 | 40 | RoW | gluconon tab 15mg, suganon tab 5mg | Yonsei University | Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes | 05/22 | 05/22 | | |
NCT05473806: Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 28 | RoW | Pioglitazone 15 Mg Oral Tablet, Gluconon tablet 15mg, Evogliptin 5mg, SUGANON tablet 5mg | Seung Up Kim | Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2 | 01/23 | 02/23 | | |
2012-004100-35: clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, on cardiovascular risk factors and on risk factors for the development of type 2 diabetes Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de riesgo cardiovascular y de desarrollo de diabetes tipo 2. |
|
|
| Ongoing | 3 | 40 | Europe | Metformina, espironolactona, Clorhidrato de pioglitazona, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO | Fundació per la Recerca i la Docència Sant Joan de Déu, Ministerio de Sanidad y Política Social | Ovarian hyperandrogenism hiperandrogenismo ovárico | | | | |
2015-005092-24: Clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, treatment markers of pronostic and effectiveness and the development of type 2 diabetes. Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de evolución y efectividad del tratamiento y de desarrollo de diabetes tipo 2. |
|
|
| Ongoing | 3 | 40 | Europe | Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO, Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO | FUNDACIÓ SANT JOAN DE DÉU, Ministerio de Sanidad y Política Social | ovarian hyperandrogenism with hyperinsulinaemia hiperandrogenismo ovárico con hiperinsulinismo | | | | |
NCT05422092: Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease |
|
|
| Not yet recruiting | N/A | 80 | NA | Canagliflozin, Canagliflozin tablets, Pioglitazone, Pioglitazone Hydrochloride Tablets | First Affiliated Hospital Xi'an Jiaotong University | Type 2 Diabetes Mellitus With Complication | 01/23 | 12/23 | | |
NCT05513729: Effect of Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease |
|
|
| Recruiting | N/A | 80 | RoW | Canagliflozin, Canagliflozin tablets, Pioglitazone, Pioglitazone Hydrochloride Tablets | First Affiliated Hospital Xi'an Jiaotong University | Type 2 Diabetes Mellitus With Complication | 12/23 | 03/24 | | |
